LM11A 31 dihydrochloride
Nonpeptide p75NTR ligand; blocks p75-mediated cell death and also increases proliferation and survival of hippocampal neural progenitors. Exhibits no effect on nerve growth factor (NGF) binding to TrkA. Prevents and reverses atrophy of cholinergic neurites, as well as reversing Alzheimer's Disease (AD) pathologies in mid- to late-stage AD mice models. Shown to promote functional recovery in a mouse model of spinal cord injury. Orally available and brain penetrant.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 316.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.16 mL||15.81 mL||31.62 mL|
|5 mM||0.63 mL||3.16 mL||6.32 mL|
|10 mM||0.32 mL||1.58 mL||3.16 mL|
|50 mM||0.06 mL||0.32 mL||0.63 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Shi et al (2013) A small molecule P75NTR ligand protects neurogenesis after traumatic brain injury. Stem Cells [Epub ahead of print] PMID: 23940017
Massa et al (2006) Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J.Neurosci. 26 5288 PMID: 6707781
Tep et al (2013) Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J.Neurosci. 33 397 PMID: 23303920
Simmons et al (2014) A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One 9 e102136 PMID: 25153701
If you know of a relevant reference for LM11A 31 dihydrochloride, please let us know.
View Related Products by Target
Keywords: LM11A31 dihydrochloride p75NTR ligands selective NGFR nerve growth factor receptors Alzheimer's Disease neuroprotective Trk Receptors
Citations for LM11A 31 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for LM11A 31 dihydrochloride. Do you know of a great paper that uses LM11A 31 dihydrochloride from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.